Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using Amyloid-Reactive Peptide 124I-AT-01 (124I-p5+14, Iodine-124I-Evuzamitide) to Measure Changes in Organ-Specific Amyloid Load
Conditions
Interventions
124I AT-01
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
September 10, 2025
Primary Completion Date
July 1, 2031
Completion Date
January 31, 2032
Last Updated
April 8, 2026
NCT06355934
NCT06427304
NCT06383143
NCT06672237
NCT05758493
NCT07213297
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions